AACR 101st Annual Meeting 2010, Washington D.C. Experimental and Molecular Therapeutics Section 29; Abstract #3855
|
|
- Gabriel Daniel
- 6 years ago
- Views:
Transcription
1 Investigation of the Growth Inhibitory Activity of the MEK Inhibitor ARRY-162 in Combination with Everolimus in a Variety of KRas and PI3K Pathway Mutant Cancers Brian Tunquist, Tyler Risom, Debbie Anderson, Jennifer Garrus, Shannon Winski, Eli Wallace, Jim Winkler, Kevin Koch, Patrice Lee, Duncan Walker, and Stefan Gross AACR 101st Annual Meeting 2010, Washington D.C. Experimental and Molecular Therapeutics Section 29; Abstract #3855
2 Inhibition of the Raf/MEK/ERK Pathway in Oncology Oncogenic mutations of certain receptor tyrosine kinases (RTK), Ras, and Raf frequently manifest in constitutive activation of MEK1/2 and ERK1/2 kinases. This pathway has attracted much attention in the search for new chemotherapeutics, and small molecule inhibitors of MEK1/2 have been identified. ARRY-162 is a potent and selective inhibitor of MEK1/2: RTKs frequently mutated in cancers Ras Raf MEK1/2 ARRY-162 ERK1/2 Cell Proliferation
3 Inhibition of the RAF/MEK/ERK Pathway in Oncology Mutation of Raf, and to some extent, Ras, confers sensitivity to the MEK inhibitor AZD6244 (ARRY ). Mutational activation of the PI3K pathway correlates with resistance. Dry et al, Cancer Res, 2010
4 Ras Activation of PI3K and Raf Pathways in Cancer Ras activates the PI3K and Raf/MEK/Erk signaling pathway. The PI3K pathway may compensate for the loss of Raf/MEK/Erk signaling. RTKs Ras PTEN PI3K PDK1 AKT Crosstalk Raf MEK ERK ARRY-162 FOXO RSK Cell survival frequently mutated in cancers TORC1 S6K 4EBP1 Cell Growth, Metabolism Cell Proliferation, Angiogenesis
5 Inhibition of MEK and mtor Signaling Pathways Would inhibition of Raf/MEK/ERK and mtor signaling pathways yield greater activity in the clinic through enhanced disruption of survival and proliferation signals? RTKs Ras PTEN PI3K PDK1 AKT Crosstalk Raf MEK ERK ARRY-162 FOXO Everolimus RSK Cell survival frequently mutated in cancers TORC1 S6K 4EBP1 Cell Growth, Metabolism Cell Proliferation, Angiogenesis
6 Experimental Design Cell Lines: 47 in total encompassing a wide range of tumor types and mutational status Specifically, mutation of BRaf, Ras, PIK3CA, and PTEN genes were of interest. Assay: Proliferation (Alamar Blue, DNA), 3-5 day duration Compounds: Everolimus: 10 nm (minimum concentration yielding maximum growth inhibition across all lines) ARRY-162: 10, 30 & 100 nm (2x, 6x and 20x mechanistic cell IC 50 ) Combination Activity Determination: Bliss Method of Fractional Independence (Bliss, CI. Ann Appl Biol. 1939; 26: ) Combination Index Antagonism Independence Additivity Synergism
7 ARRY-162 and everolimus in vitro Combination Activity in Malme3M Cells 100 percent of control (POC) CI = 0.44 Combination Index Antagonism Independence/ Additivity Synergism 0 100nM ARRY nM everolimus combination percent of control (POC) [ARRY-162] (μm) [everolimus] (nm)
8 Tumor Cell Line Data Summary: 100 nm ARRY nm Everolimus Combination Tumor Cell Lines (grouped by genotype) 1.5 Antagonism Combination Index (CI) Independence/ Additivity Synergy WT Raf/Ras Mut Raf or Ras - Enhanced combinatorial activity in Ras or Raf mutant tumor cell lines: - majority of cell lines exhibit a CI value of less than 1 - many of the cell lines exhibit synergy (CI < 0.8)
9 Further Stratification Based Upon PI3K Pathway Mutation Tumor Cell Lines (grouped by genotype) 1.5 Antagonism Combination Index (CI) 1.0 Independence/ Additivity Synergy 0.5 WT Raf/Ras Mut Raf or Ras WT Raf/Ras Mut Raf or Ras WT Raf/Ras Mut Raf or Ras PIK3CA PTEN Mutation - Combination activity may not be enhanced with an additional mutation of PI3K, while tumors with a PTEN mutation may respond negatively. - Experiments analyzing the effect of PTEN knockdown in sensitive cell lines are underway.
10 Does in vitro combination activity translate in vivo? Tumor Cell Lines (grouped by genotype) 1.5 Antagonism Combination Index (CI) SW620 NCI-H460 Independence/ Additivity Synergy WT Raf/Ras Mut Raf or Ras - SW620 colorectal cancer tumor cell line: KRas (G12V), CI = NCI-H460 lung cancer tumor cell line: KRas (Q61H), PI3KCA (E545K), CI = 0.73
11 in vivo Comparison of SW620 and NCI-H460 Cell Lines SW620 NCI-H460 Tumor Volume (mm3) Day of Study Vehicle Everolimus, 2.5 mg/kg, QDx12 ARRY-162, 100 mg/kg, BIDx13 ARRY-162, 100 mg/kg, BIDx13 Everolimus, 2.5 mg/kg, QDx Day of Study Vehicle Everolimus, 2.5 mg/kg, QDx12 ARRY-162, 100 mg/kg, BIDx16 ARRY-162, 100 mg/kg, BIDx16 Everolimus, 1 mg/kg, QDx16 - in vitro combination activity is consistent with in vivo xenograft data. Deb Anderson/Shannon Winski
12 Pathway Inhibition Comparison SW620 NCI-H460 SW620 NCI-H460 ARRY-162 (100nM) Everolimus (10nM) ARRY-162 (100nM) Everolimus (10nM) Phospho-Erk1/2 (T202/Y204) Phospho-eIF 4EBP1 (Thr37/46) Erk1/2 Phospho-S6 (Ser235/236) Phospho-Akt (S473) PTEN LKB1/STK11 Phospho-Akt (T308) GAPDH Akt - Decreased perk levels by ARRY Unable to identify markers of sensitivity/resistance to the combination.
13 Profiling Apoptosis and Cell Cycle Regulators SW620 NCI-H460 SW620 NCI-H460 ARRY-162 (100nM) Everolimus (10nM) ARRY-162 (100nM) Everolimus (10nM) Bim p27 Kip1 Phospho-Rb (Ser608) Mcl-1 GAPDH Rb GAPDH - No change seen in levels of Bcl-2, Bcl-X L, Bid, NOXA, or cleaved PARP (not shown). - Regulation of Bim, p27 Kip1, and Rb proteins by MEK inhibitors has been reported. - Unable to identify markers of sensitivity/resistance to the combination.
14 Summary ARRY-162 is a potent and selective inhibitor of MEK1/2 Combination activity of ARRY-162 and everolimus may be enhanced by selection of tumors with specific genetic alterations: Mutation of Ras or Raf is a potential marker of additivity/synergy No clear impact from mutation of PI3K or PTEN Possible exception is PTEN in wildtype cell lines Investigations are underway to determine whether loss of PTEN is able to decrease combination activity in sensitive cells Combination activity in vitro correlates with activity in vivo Analysis of obvious pathway components has not revealed biomarkers of sensitivity/resistance to the combination thus far.
15 Preliminary Implications Patient Selection: Patients with mutations in Ras or Raf may benefit from ARRY-162/everolimus combination treatment Patients with mutation of PI3K may also benefit from this combination Patients with a loss of function mutation in PTEN may not respond to this combination Key indications with a high incidence of Ras or Raf mutations include: melanoma NSCLC colorectal cancer Cell Autonomous vs. Tumor Microenvironment Additional benefit may be gained from effects of this combination on tumor hypoxia and metabolism. ARRY-162 is currently in a Phase 1 study in patients with solid tumors.
Development of Rational Drug Combinations for Oncology Indications - An Industry Perspective
Development of Rational Drug Combinations for Oncology Indications An Industry Perspective Stuart Lutzker, MDPhD Vice President Oncology Early Development Genentech Inc 1 Conventional Oncology Drug Development
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationmtor Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-
Supplementary Material for mtor Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL- XL Inhibition by Suppressing MCL-1 Anthony C. Faber 1,2 *, Erin M. Coffee
More informationResponse and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
More informationPre-clinical PK/PD modelling of combination therapies in oncology: abemaciclib and vemurafenib
Pre-clinical PK/PD modelling of combination therapies in oncology: abemaciclib and vemurafenib Combination Therapies in Oncology Combination therapies in oncology have been explored and used for many decades
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationNature Medicine: doi: /nm.3559
Supplementary Note 1. A sample alteration report. Each alteration nominated by PHIAL is curated to answer specific fields that are intended to guide physician interpretation. Gene Alteration Patient ID
More informationThe PI3K/AKT axis. Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia. Introduction
The PI3K/AKT axis Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia Introduction Phosphoinositide 3-kinase (PI3K) pathway are a family of lipid kinases discovered in 1980s. They have
More informationRob Ross, MD. Infinity Pharmaceuticals March 9 th, 2011
Heat Shock Protein 90 (Hsp90) Inhibition as a Potential Novel Approach to the Treatment of Patients with ALK Mutated Non-small Cell Lung Cancer (NSCLC) Rob Ross, MD Infinity Pharmaceuticals March 9 th,
More informationKRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS
UNIVERSITÀ DEGLI STUDI DI PALERMO Scuola di Specializzazione in Biochimica Clinica Direttore Prof. Marcello Ciaccio KRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS Loredana Bruno KRAS gene Proto-oncogene
More informationThe selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance
The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance Ursula Germann 1, Brinley Furey 2, Jeff Roix 3, William
More informationTargeting the PI3K Pathway in the Therapy of Breast Cancer: Current Status and Future Directions. José Baselga MD, PhD Physician-in-Chief
Targeting the PI3K Pathway in the Therapy of Breast Cancer: Current Status and Future Directions José Baselga MD, PhD Physician-in-Chief PI3K and Breast Cancer Overview The Pathway PI3K drives resistance
More informationEGFR: fundamenteel en klinisch
EGFR: fundamenteel en klinisch Guido Lammering MAASTRO Clinic Maastricht, NL What is EGFR?? The EGFR some facts 1186 amino acids 170 kda Expressed by all cells of epithelial origin Increased activation
More informationSupplementary Figure 1. a. b. Relative cell viability. Nature Genetics: doi: /ng SCR shyap1-1 shyap
Supplementary Figure 1. a. b. p-value for depletion in vehicle (DMSO) 1e-05 1e-03 1e-01 1 0 1000 2000 3000 4000 5000 Genes log2 normalized shrna counts in T0 0 2 4 6 8 sh1 shluc 0 2 4 6 8 log2 normalized
More informationSupplementary Figure 1. Basal level EGFR across a panel of ESCC lines. Immunoblots demonstrate the expression of phosphorylated and total EGFR as
Supplementary Figure 1. Basal level EGFR across a panel of ESCC lines. Immunoblots demonstrate the expression of phosphorylated and total EGFR as well as their downstream effectors across a panel of ESCC
More informationUnderstanding Signaling Pathways by Modifying Sensitivity to PLX4720 in B-RAF V600E Melanoma
Understanding Signaling Pathways by Modifying Sensitivity to PLX4720 in B-RAF V600E Melanoma Muska Hassan NCI-ICBP Summer Fellow Broad Institute of MIT and Harvard: Cancer Program Mentor: Cory Johannessen,
More informationPhosphorylation Site Company Cat #
Supplemental Table 1. Antibodies used for RPPA analysis. Label Protein Phosphorylation Site Company Cat # Used on MDA_CLSS Used on MDA_Pilot 4EBP1 4EBP1 Cell Signaling 9452 No 4EBP1.pS65 4EBP1 S65 Cell
More informationKinome Profiling: The Potential in ER-Negative Patients. Charles M. Perou, Ph.D. Departments of Genetics and Pathology
Kinome Profiling: The Potential in ER-Negative Patients Charles M. Perou, Ph.D. Departments of Genetics and Pathology Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill, North
More informationBL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:
More informationCombinations of targeted therapies in oncology an industry view
Combinations of targeted therapies in oncology an industry view Dr Susan Galbraith SVP Head of Oncology imed AstraZeneca WIN 2014 Symposium 23-24 June Paris France Disclosures I am a full time employee
More informationConverting Novel Therapeutic Models into Early Phase Clinical Trials
Converting Novel Therapeutic Models into Early Phase Clinical Trials James H. Doroshow, M.D. Deputy Director for Clinical and Translational Research National Cancer Institute, NIH IOM National Cancer Policy
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): The authors have presented data demonstrating activation of AKT as a common resistance mechanism in EGFR mutation positive, EGFR TKI resistant
More informationComplexity of intra- and inter-pathway loops in colon cancer and melanoma: implications for targeted therapies
Complexity of intra- and inter-pathway loops in colon cancer and melanoma: implications for targeted therapies René Bernards The Netherlands Cancer Institute Amsterdam The Netherlands Molecular versus
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature23291 Supplementary discussion part 1 Our model suggests that, in tumours that express Class 3 BRAF mutants and activated RAS, both BRAF MUT /RAF WT heterodimers and WT RAF dimers are
More informationHeat shock proteins as an emerging therapeutic target
UNIVERSITY OF OF TORINO DEPARTMENT OF ONCOLOGY Heat shock proteins as an emerging therapeutic target Giorgio V. Scagliotti University of Torino Professor of Medical Oncology Department of Oncology giorgio.scagliotti@unito.it
More informationPKPD models to describe the growth and inhibition of xenograft tumors by
Applying mechanistic c PKPD models to describe the growth and inhibition of xenograft tumors by targeted anti-cancer agents. James WT Yates, Neil Evans, RD Owen Jones, Mike Walker, Patricia Schroeder,
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More informationDifferential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation, and tumor progression in the colon
SUPPLEMENTARY INFORMATION Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation, and tumor progression in the colon Kevin M. Haigis, Krystle Kendall, Yufang Wang, Ann Cheung,
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationPI3K Background. The SignalRx R & D pipeline is shown below followed by a brief description of each program:
PI3K Background The phosphatidylinositol 3-kinase (PI3K) pathway is a key cell signaling node whose dysregulation commonly results in the transformation of normal cells into cancer cells. The role of PI3K
More informationMATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS
MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS DR. RACHEL E. LAING*, OLIVIER LESUEUR*, STAN HOPKINS AND DR. SEAN X. HU MAY 2012 Recent advances in oncology, such
More informationPlanar Waveguides: How Nano Layers Enable to Detect Zepto Moles of Macro Molecules in Pico Liter Spots on Micro Arrays
Planar Waveguides: How Nano Layers Enable to Detect Zepto Moles of Macro Molecules in Pico Liter Spots on Micro Arrays Dr. Markus Ehrat Zeptosens A Division of Bayer Schweiz AG SSOM Meeting March 16 /17
More informationIdentification of BRAF mutations in melanoma lesions with the Roche z480 instrument
Identification of BRAF mutations in melanoma lesions with the Roche z480 instrument Márta Széll IAP, Siófok May 14, 2012 Multifactorial skin diseses: much more frequent then genodermatoses exhibit familial
More informationAntitumor Activity of CUDC-305, a Novel Oral HSP90 Inhibitor, in Solid and Hematological Tumor Xenograft Models
Antitumor Activity of CUDC-5, a Novel Oral HSP Inhibitor, in Solid and Hematological Tumor Xenograft Models Rudi Bao, MD/PhD April 1, 2 AACR 1th Annual Meeting 2 Experimental and Molecular Therapeutics
More informationDevelopment of Circulating Tumor DNA
Development of Circulating Tumor DNA Title of presentation Arial Bold 30pt in White Biomarkers Secondary title 22pt using Arial Next in White Generation Sequencing Brian Dougherty PhD, MBA Translational
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationTargeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor
Targeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor Josep Tabernero, Andrés Cervantes, Cristina Saura, Desamparados Roda, Yibing Yan, Kui Lin, Sumati Murli,
More informationGENETIC ANALYSIS OF RAS SIGNALING PATHWAYS IN CELL PROLIFERATION, MIGRATION AND SURVIVAL
Manuscript EMBO-2009-72496 GENETIC ANALYSIS OF RAS SIGNALING PATHWAYS IN CELL PROLIFERATION, MIGRATION AND SURVIVAL Matthias Drosten, Alma Dhawahir, Eleanor Sum, Jelena Urosevic, Carmen Lechuga, Luis Esteban,
More informationLa vía PI3K como diana: abordaje y nuevas estrategias en resistencias
La vía PI3K como diana: abordaje y nuevas estrategias en resistencias Ana Maria Gonzalez-Angulo, M.D. Associate Professor Section Chief, Clinical Research and Drug Development Breast Medical Oncology Systems
More informationTargets & therapies for colorectal cancer
Targets & therapies for colorectal cancer Jan Schellens Werkgroep "MOLECULAIRE DIAGNOSTIEK IN DE PATHOLOGIE 31-01-2014 Current treatment options for advanced colorectal cancer (CRC) First line: - CAPOX
More informationAntitumor activity of the ERK inhibitor SCH against BRAF mutant, NRAS mutant and wild-type melanoma
Wong et al. Molecular Cancer 2014, 13:194 RESEARCH Open Access Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma Deborah JL Wong 1, Lidia Robert
More informationLooking Beyond the Standard-of- Care : The Clinical Trial Option
1 Looking Beyond the Standard-of- Care : The Clinical Trial Option Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor
More informationSupplementary Figures
Supplementary Figures Figure S1. Validation of kinase regulators of ONC201 sensitivity. Validation and screen results for changes in cell viability associated with the combination of ONC201 treatment (1
More informationDiagnostic test Suggested website label Description Hospitals available
Diagnostic test Suggested website label Description Hospitals available Abbott Molecular Inc, PATHVYSION HER-2 DNA Probe Kit (FISH) PathVysion kit A diagnostic tool used to determine whether a particular
More informationmtor plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions
Supplementary Information mtor plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions Shyuichiro Matsubara 1, Qiang Ding 1, Yumi Miyazaki 1, Taisaku Kuwahata
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION doi:.38/nature83 Supplementary figure An Overview of Experimental Flow Hypothesis: The tumor microenvironment has a significant impact on cancer cell chemoresistance. Screen Coculture
More informationTargeting mtor pathway in ER+/Her2- breast cancers. Fabrice ANDRE Gustave Roussy
Targeting mtor pathway in ER+/Her2- breast cancers Fabrice ANDRE Gustave Roussy Outline mtor pathway Clinical development of rapalogs in breast cancer Moving beyond rapalogs mtor pathway LKB1 Ras-raf-
More informationNew Developments in Thyroid Cancer
New Developments in Thyroid Cancer Eric J. Sherman, MD Professor Vice-Chair for Clinical Operations Chief, Division of Head and Neck Surgery Departments of Otolaryngology, Radiation Oncology, and Immunology
More informationLeucine Deprivation Reveals a Targetable Liability
Cancer Cell, 19 Supplemental Information Defective Regulation of Autophagy upon Leucine Deprivation Reveals a Targetable Liability of Human Melanoma Cells In Vitro and In Vivo Joon-Ho Sheen, Roberto Zoncu,
More informationPIK3CA mutations enable targeting of a breast tumor dependency through mtor-mediated MCL-1 translation
CANCER PIK3CA mutations enable targeting of a breast tumor dependency through mtor-mediated MCL-1 translation 2016 The Authors, some rights reserved; exclusive licensee American Association for the Advancement
More informationBRAF inhibitors Anti-angiogenic therapy Other molecular targets Discussion
If you experience any technical difficulties call 8-274-939 or e-mail informed@commpartners.com Slides will advance automatically. You can also advance/ review the presentation using the control buttons
More informationALM301: Allosteric Isoform selective Akt inhibitor
ALM301: Allosteric Isoform selective Akt inhibitor Background Akt1/2 selective inhibitors ALM301 Back-up compounds Akt2 selective inhibitors Approaches to Akt Inhibition Both ATP competitive and allosteric
More informationContents. Preface XV Acknowledgments XXI List of Abbreviations XXIII About the Companion Website XXIX
Contents Preface XV Acknowledgments XXI List of Abbreviations XXIII About the Companion Website XXIX 1 General Aspects of Signal Transduction and Cancer Therapy 1 1.1 General Principles of Signal Transduction
More informationDevelopments in small cell lung cancer G. Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliates National Cancer Institute Bethesda MD USA
Developments in small cell lung cancer G. Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliates National Cancer Institute Bethesda MD USA Geneva April 20, 2012 Neuroendocrine tumors of lung Typical
More informationmtor e le altre vie di trasduzione del segnale: Implicazioni cliniche Giampaolo Tortora
mtor e le altre vie di trasduzione del segnale: Implicazioni cliniche Giampaolo Tortora Cattedra di Oncologia Medica UOC Oncologia Medica du Facoltà di Medicina e Chirurgia e Azienda Ospedaliera Universitaria
More informationNormal Skin. Tissue Samples and Melanoma Cell Lines. BRAF Mut. RAS Mut RAS WT /BRAF WT
Supplemental Figure 1. MERTK gene expression in melanoma cell line panel from Cancer Cell Line Encyclopedia. A. Microarray analysis of melanoma cell lines from UNC collection grouped by oncogenic mutation.
More informationPIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
More informationCorporate Overview. April 2016
Corporate Overview April 2016 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationw ª wy xvwz A ª vw xvw P ª w} xvw w Æ w Æ V w,x Æ w Æ w Æ y,z Æ { Æ y,z, w w w~ w wy}æ zy Æ wyw{ xæ wz w xywæ xx Æ wv Æ } w x w x w Æ w Æ wy} zy Æ wz
w ª wy xvwz A ª vw xvw P ª w} xvw w Æ w Æ V w,x Æ w Æ w Æ y,z Æ { Æ y,z, w w w~ w wy}æ zy Æ wyw{ xæ wz w xywæ xx Æ wv Æ } w x w x w Æ w Æ wy} zy Æ wz {w Æ Æ wyw{ x w Germ-line mutations in BRCA1 are associated
More informationAWARD NUMBER: W81XWH TITLE: An in Vivo shrna-drug Screen to Identify Novel Targeted Therapy Combinations for KRAS Mutant Cancers
AWARD NUMBER: W81XWH-12-1-0420 TITLE: An in Vivo shrna-drug Screen to Identify Novel Targeted Therapy Combinations for KRAS Mutant Cancers PRINCIPAL INVESTIGATOR: Ryan B. Corcoran, M.D., Ph.D. CONTRACTING
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationBiology of Renal Cell Cancer. Disclosures
Biology of Renal Cell Cancer Dr Joseph Ischia Uro-oncology Fellow 14-3-2012 No patents No honorariums Not on any boards Disclosures Essendon supporter 1 Renal Cell Cancer 2% of new cancers 30% have metastatic
More informationEnlarge Slides. One Moment Please. Skin Cancer. Thomas Olencki, DO David Carr, MD. Today s Webcast Friday, 09/09/11, Noon
New Features Enlarge Slides Links One Moment Please Chapters Polling Use the email function to let us know what you think One Moment Please Skin Cancer Thomas Olencki, DO David Carr, MD Today s Webcast
More informationCLINICAL UPDATE ON K-RAS
CLINICAL UPDATE ON K-RAS TARGETED THERAPY IN GASTROINTESTINAL CANCERS S. PA N T, 1 J. H U B B A R D, 2 E. M A RT I N E L L I, 3 A N D T. B E K A I I - S A A B 4 SELECTED HIGHLIGHTS 1 Department of Investigational
More informationDaniele Santini University Campus Bio-Medico Rome, Italy
Daniele Santini University Campus Bio-Medico Rome, Italy Anti EGFR therapy and colorectal cancer Cetuximab or Panitumumab Adapted from Ciardiello F. and Tortora G. NEJM 2008;358:1160-74 Who will benefit
More informationras Multikinase Inhibitor Multikinase Inhibitor 0.1
a ras ** * ** * ** ** ** ** un in et m lu Se ib SL G 32 W 7 So 50 ra 74 fe ni b LY W 294 or 0 tm 02 R an ap n a in Ev my er cin ol im BE us Z2 3 En P 5 za I13 st 0 au rin D as SP ati 60 nib C 012 is 5
More informationRSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Amendment history: Corrigendum (March 2014) RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer Violeta Serra,, So Young Kim, José Baselga J Clin Invest. 2013;123(6):2551-2563. https://doi.org/10.1172/jci66343.
More informationUnderstanding PI3K/mTOR/MEK signalling in breast cancer. Euphemia Leung Auckland Cancer Society Research Centre University of Auckland
Understanding PI3K/mTOR/MEK signalling in breast cancer Euphemia Leung Auckland Cancer Society Research Centre University of Auckland Receptor status of human breast cancer On a popula>on basis ER+/PR+
More informationSupplementary Material. Part I: Sample Information. Part II: Pathway Information
Supplementary Material Part I: Sample Information Three NPC cell lines, CNE1, CNE2, and HK1 were treated with CYC202. Gene expression of 380 selected genes were collected at 0, 2, 4, 6, 12 and 24 hours
More informationCONTRACTING ORGANIZATION: Massachusetts General Hospital Boston, MA
AD Award Number: W81XWH-12-1-0420 TITLE: An in vivo shrna-drug screen to identify novel targeted therapy combinations for KRAS mutant cancers PRINCIPAL INVESTIGATOR: Ryan B. Corcoran, MD PhD CONTRACTING
More informationDox. R26-rtTA Tyr-CreERT2. any ink/arf, no rtta (n=8) ink/arf +/+ (n=5) Day 0 Day 11 Day 18 Day 28
A 4OHT Dox hraf iip tumors inras ddh 2 O -RT Ink/Arf / Pten l/ l R26-lsl-rtTA Tyr-reERT2 TetO-hRAF V6E Ink/Arf / Pten / R26-rtTA Tyr-reERT2 TetO-hRAF V6E Ink/Arf / Pten / R26-rtTA Tyr-reERT2 TetO-hRAF
More informationSupplementary Material
Supplementary Material The Androgen Receptor is a negative regulator of eif4e Phosphorylation at S209: Implications for the use of mtor inhibitors in advanced prostate cancer Supplementary Figures Supplemental
More informationSignal Transduction Pathway Smorgasbord
Molecular Cell Biology Lecture. Oct 28, 2014 Signal Transduction Pathway Smorgasbord Ron Bose, MD PhD Biochemistry and Molecular Cell Biology Programs Washington University School of Medicine Outline 1.
More informationBiologics Effects of Targeted Therapeutics
Report on the isbtc Mini-symposium on Biologics Effects of Targeted Therapeutics Michael B. Atkins, MD Beth Israel Deaconess Medical Center Louis Weiner, M.D. Fox Chase Cancer Center Report on the isbtc
More informationSupplementary Figure 1. BMS enhances human T cell activation in vitro in a
Supplementary Figure 1. BMS98662 enhances human T cell activation in vitro in a concentration-dependent manner. Jurkat T cells were activated with anti-cd3 and anti-cd28 antibody in the presence of titrated
More informationA View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
More informationp53 and Apoptosis: Master Guardian and Executioner Part 2
p53 and Apoptosis: Master Guardian and Executioner Part 2 p14arf in human cells is a antagonist of Mdm2. The expression of ARF causes a rapid increase in p53 levels, so what would you suggest?.. The enemy
More informationblood mononuclear cells were stained with AAD, annexin, CD3, CD4, CD25, LAP and specific
Supplementary figure legends Figure 1: Selective expression of regulatory markers on CD4 + LAP + T cells. Human peripheral blood mononuclear cells were stained with AAD, annexin, CD3, CD4, CD25, LAP and
More informationPF , HKI 272 XL647, BIBW
Targeted Therapy for Lung Cancer? Emerging Novel targets for NSCLC 11 th UCSF/UCD Thoracic Oncology Conference 11/21/29 Sarita Dubey, M.D., Medical Oncology University of California, San Francisco Cytotoxic
More informationA particular set of insults induces apoptosis (part 1), which, if inhibited, can switch to autophagy. At least in some cellular settings, autophagy se
A particular set of insults induces apoptosis (part 1), which, if inhibited, can switch to autophagy. At least in some cellular settings, autophagy serves as a defence mechanism that prevents or retards
More informationOverview of New Drugs for GIST following resistance to standard TKIs (imatinib and sunitinib)
Overview of New Drugs for GIST following resistance to standard TKIs (imatinib and sunitinib) George D. Demetri, M.D. Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Harvard Medical School
More informationThe AZ-Merck Collaboration
The AZ-Merck Collaboration Institute of Medicine Washington, D.C. 10 Feb 2010 Pearl S. Huang, Ph.D. VP Oncology, Merck and Co. On behalf of the AZ/Merck Collaboration Team Combination Therapy is Standard
More informationSelecting the right patients for the right trials.
Selecting the right patients for the right trials. Paul Waring Professor of Pathology University of Melbourne June 21, 2011 RCPA Genetics short course Drug development challenges. Current model of drug
More informationDeveloping Effective and Tolerable Combinations. Dr Susan Galbraith, SVP & Head imed Oncology June 2016
Developing Effective and Tolerable Combinations Dr Susan Galbraith, SVP & Head imed Oncology June 2016 Disclosures I am a full time employee of AstraZeneca UK I hold AstraZeneca shares I will mention non-approved
More informationTratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt
Tratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt University Neoadjuvant (preoperative) therapy Surgery Systemic
More informationReceptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
Research article Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers Hiromichi Ebi, 1,2 Ryan B. Corcoran, 1,2 Anurag Singh, 1,2 Zhao Chen, 2,3 Youngchul
More informationThe Multi-faceted Role of the PI3K-AKT Pathway in Melanoma
The Multi-faceted Role of the PI3K-AKT Pathway in Melanoma Melanoma Bridges Naples, Italy December 4, 2014 Michael A. Davies, M.D., Ph.D. Associate Professor Melanoma Medical Oncology and Systems Biology
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationWNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
Research article WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors Jamie N. Anastas, 1,2 Rima M. Kulikauskas, 3 Tigist Tamir, 4 Helen Rizos, 5 Georgina V. Long, 5 Erika M. von Euw,
More informationSupplementary Figure 1
Combination index (CI) Supplementary Figure 1 2. 1.5 1. Ishikawa AN3CA Nou-1 Hec-18.5...2.4.6.8 1. Fraction affected (Fa) Supplementary Figure 1. The synergistic effect of PARP inhibitor and PI3K inhibitor
More informationTargeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation
Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation James Chih-Hsin Yang, MD, PhD National Taiwan University Hospital National Taiwan University Cancer Center Taipei, Taiwan
More informationTargeting RAS pathways in myeloma
in partnership with Targeting RAS pathways in myeloma Dr Martin Kaiser, The Institute of Cancer Research UKMF Spring Day 2015 Making the discoveries that defeat cancer Outline 2 1) What is RAS and what
More informationOne Moment Please. Skin Cancer. Today s Webcast Friday, 09/09/11, Noon. David Carr, MD
One Moment Please One Moment Please Skin Cancer Thomas Olencki, DO David Carr, MD Today s Webcast Friday, 09/09/11, Noon 1 New Features Enlarge Slides Links Chapters Polling Use the email function to let
More informationWHY TARGETTING SIGNALLING PATHWAYS?
WHY TARGETTING SIGNALLING PATHWAYS? Cancer cells are particularly sensitive to stress therefore sensitive to inhibition of their hyper activated signaling proteins the re instatement of lost tumor suppressors.
More informationTreatment Landscape in R/R DLBCL Novel Targets and Strategies. Wyndham H. Wilson, M.D., Ph.D. Senior Investigator
Treatment Landscape in R/R DLBCL Novel Targets and Strategies Wyndham H. Wilson, M.D., Ph.D. Senior Investigator Gene-expression profiling of DLBCL subtypes Roschewski, M. et al. (2013) Nat. Rev. Clin.
More informationPersonalizing Myeloma Treatment Drugs and Strategies
Personalizing Myeloma Treatment Drugs and Strategies PD Dr. med. Marc S. Raab Heidelberg University Medical Center & German Cancer Research Center Multiple Myeloma Clonal proliferation of malignant plasma
More informationCompany Update. December 2007
Company Update December 2007 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of the Private
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More information